Remission for a global epidemic of obesity, pre-diabetes, and type 2 diabetes
The HEALcare® program can control and put into remission three AMA-recognized diseases affecting 170 million Americans and over 1 billion across the globe: obesity, pre-diabetes, and type 2 diabetes. Traditional treatments rarely ever put these diseases into remission.WATCH VIDEO
The HEALcare® difference:
Our mission is remission
Obesity remission through dietary, medical and commitment support
Unlike retail weight-loss franchises, HEALcare is a highly personalized program based on a low-carbohydrate lifestyle proven to control obesity. Combining one-on-one and group support, HEALcare delivers diet and nutrition advice, commitment coaching, medical evaluation and continuing medical oversight as needed.
Remission for pre-diabetes and type 2 diabetes without “pills & needles” in seven weeks
The HEALcare low-carbohydrate health and wellness program for pre-diabetes and type 2 diabetes ensures lifelong optimal health outcomes without medication or insulin in as little as seven weeks or sooner.
The HEAL Clinics Business Model
The HEAL Clinics medical team is led by Eric Westman, MD, MHS, also Director of the Lifestyle Medicine Clinic at Duke University.
The HEAL Clinics business team is led by Bruce Rossiter, JD, MBA, a veteran venture capitalist and former McKinsey & Company associate.
The team also includes clinical and other recognized veterans of hospital administration, investment firms, and life-science companies. Learn more.
HEAL Clinics by the numbers…
Percentage of the U.S. population suffering from obesity, pre-diabetes, and type-2 diabetes—about 170 million people.
Annual amount spent by the average individual with diabetes after third-party reimbursements.
Annual amount spent by all health systems to treat type-2 diabetes, pre-diabetes, and obesity and their associated disorders.
Typical number of weeks required under HEALcare to put type 2 diabetes and pre-diabetes into remission.
Projected number of HEAL Clinics patients served through the company’s fifth year of operation.
Projected growth in the company’s price per share by the year 2021.